Latest action: Referred to the House Committee on Energy and Commerce.
Referred to one or more standing committees for review, hearings, and possible markup.
Specific committees not parsed from action data.
The committee may hold hearings, amend the bill, or let it die without action.
Next: Reported
Full chamber floor — Speaker / Majority Leader controls scheduling
Speeds up FDA approval process for medicines made from plants.
The problem
Plant-based drugs face slow FDA review processes, delaying patient access to potentially beneficial botanical medicines compared to other drug types.
The proposal
Creates a faster regulatory pathway for botanical drug development and approval by the FDA, potentially streamlining review requirements.
The impact
Pharmaceutical companies, patients seeking plant-based treatments, and the FDA are affected. Companies gain faster market access; patients may reach new medicines sooner.
Accelerating botanical drug approval could help patients receive plant-based treatments more quickly. This is particularly important for patients preferring natural remedies or those with limited options for their conditions.
A clearer regulatory pathway encourages investment and innovation in botanical medicine companies. This could create jobs and economic activity in the plant-based pharmaceutical sector.
Reduced barriers encourage companies to invest in studying plant-based compounds. This could unlock new medicines from natural sources previously considered too burdensome to develop.
A streamlined pathway helps U.S. companies compete internationally in botanical drug markets. Other countries are advancing plant-based medicine development, and this supports domestic industry.
Faster approval pathways might compromise thorough safety testing if standards are reduced. Plant compounds can have unpredictable effects, and rushed review could miss harmful side effects or drug interactions.
Botanical products vary widely in composition and strength depending on growing conditions. Faster approval might allow products with unproven effectiveness onto the market, misleading patients.
Creating a separate pathway adds complexity to FDA operations and budget needs. This could strain agency resources or create inconsistent safety standards across drug types.
Easier approval could lead to many botanical products entering the market with limited evidence. Patients might waste money on ineffective treatments while missing proven alternatives.
Generated by AI from the bill text. Not a prediction and not legal or policy advice. The percentage is the model's own rating of each item — self-reported, and not a measure of how accurate it is.
Loading map…
Loading...
0 citizens have already voted
Free · No spam · See how your representatives voted
Be the first to weigh in
Your vote starts the conversation
How citizen engagement works
Citizens vote & comment
Public opinion data is aggregated and updated in real time.
Patterns become visible
Representatives can see constituent sentiment broken down by district.
Your voice on the record
Contact your rep directly — one constituent call can shift a staffer's priority list.
Research shows that constituent contacts — especially calls — are among the most effective ways to influence a legislator's position on active bills.
Individual contributions, grouped by employer · FEC
Where their individual donors work · 2026 cycle
Money from people who work there, not from the company. Not tied to this bill.
Itemized individual contributions via FEC, grouped by the employer each contributor self-reported. Companies and unions cannot contribute to federal candidates from their treasuries, so these totals are money from people who work at an employer — never from the organization itself. They are campaign contributions covering a full election cycle and are not connected to this bill.
Senate LDA lobbying disclosures
Couldn't load lobbying disclosures right now.